Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Pediatric Therapeutics Office To Consider Ethics, Postmarket Safety

This article was originally published in The Tan Sheet

Executive Summary

FDA is in the process of hiring an epidemiologist to coordinate epidemiology and safety reviews of approved pediatric products within the newly created Office of Pediatric Therapeutics

You may also be interested in...

Pediatric research

User fee exemption for pediatric drug supplements repealed under "Best Pharmaceuticals for Children Act," signed by President Bush Jan. 4. Under the law, which reauthorizes pediatric exclusivity provisions, all pediatric supplements that require clinical data for approvals, even if the supplement is for a new indication, must pay fees unless otherwise eligible for waivers. Law also directs FDA not to delay ANDA approvals based on pediatric labeling disputes (1"The Tan Sheet" Nov. 26, 2001, p. 21)...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts